DNLI - Denali Therapeutics Inc.
19.7
-0.670 -3.401%
Share volume: 1,452,926
Last Updated: 03-05-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.04%
PREVIOUS CLOSE
CHG
CHG%
$20.37
-0.67
-0.03%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 06-30-2025 | 09-30-2025 | 12-31-2025 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
| Report Date | 05-07-2024 | 08-01-2024 | 11-06-2024 | 02-27-2025 | 05-06-2025 | 08-11-2025 | 11-06-2025 | 02-26-2026 | |
| Assets | |||||||||
| Total Assets | 1.581 B | 1.503 B | 1.454 B | 1.374 B | 1.271 B | 1.166 B | 1.056 B | 1.145 B | |
| Current Assets | 973.575 M | 928.383 M | 868.839 M | 864.436 M | 878.638 M | 934.706 M | 882.598 M | 900.658 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Investments | 876.295 M | 821.365 M | 745.923 M | 657.371 M | 760.979 M | 757.745 M | 757.241 M | 662.553 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 60.574 M | 74.679 M | 90.636 M | 174.960 M | 56.947 M | 141.207 M | 90.963 M | 205.326 M | |
| Total Non-current Assets | 490.723 M | 450.994 M | 445.463 M | 359.373 M | 235.844 M | 78.463 M | 24.703 M | 98.322 M | |
| Property Plant Equipment | 46.863 M | 48.077 M | 50.822 M | 55.236 M | 57.765 M | 58.717 M | 53.732 M | 52.402 M | |
| Other Assets | 560.653 M | 526.105 M | 534.352 M | 454.508 M | 334.940 M | 172.818 M | 119.291 M | 191.794 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 1.581 B | 1.503 B | 1.454 B | 1.374 B | 1.271 B | 1.166 B | 1.056 B | 1.145 B | |
| Total liabilities | 125.616 M | 115.514 M | 135.518 M | 144.496 M | 148.657 M | 139.188 M | 129.424 M | 131.093 M | |
| Total current liabilities | 82.582 M | 74.533 M | 87.093 M | 102.208 M | 91.877 M | 91.057 M | 90.146 M | 98.351 M | |
| Accounts Payable | 11.855 M | 13.936 M | 9.594 M | 11.137 M | 8.458 M | 10.844 M | 6.745 M | 3.330 M | |
| Other liabilities | 43.034 M | 40.981 M | 48.425 M | 42.288 M | 56.780 M | 48.131 M | 39.278 M | 32.742 M | |
| Current long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Long term debt | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other liabilities | 43.034 M | 40.981 M | 48.425 M | 42.288 M | 56.780 M | 48.131 M | 39.278 M | 32.742 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 1.455 B | 1.387 B | 1.318 B | 1.230 B | 1.123 B | 1.027 B | 926.197 M | 1.014 B | |
| Common stock | 2.675 B | 2.707 B | 2.737 B | 2.767 B | 2.793 B | 2.822 B | 2.848 B | 3.065 B | |
| Retained earnings | -1.218 B | -1.317 B | -1.424 B | -1.539 B | -1.672 B | -1.796 B | -1.923 B | -2.052 B |